Forest Laboratories Announces Health Canada Approval of Bystolic for the Treatment of Hypertension

Forest Laboratories announced that its Canadian subsidiary, Forest Laboratories Canada has received a Notice of Compliance from Health Canada for Bystolic (nebivolol) tablets, a once daily beta blocker for the treatment of hypertension.
BusinessWire